PITTSBURGH, Oct. 30, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today that the biomarker and clinical results from the recently completed Phase 1b/2a clinical study (COG0102) of CT1812 will be presented in a Late-Breaking Poster on November 2, 2017 and as a Late-Breaking Oral Communication on November 4, 2017 at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) meeting.
CT1812 is a highly brain penetrant small molecule that displaces amyloid beta (Aβ) oligomers from neuronal receptors, potentially allowing synapses to regenerate and cognitive performance to return.
“We are excited about the safety and biomarker results from this short duration clinical study, especially the observed protein changes in CT1812 treated patients compared to placebo treated patients related to CT1812’s synaptic recovery mechanism of action,” commented Susan Catalano, Ph.D., Cognition Therapeutics’ chief scientific officer and founder. “These results provide valuable insights into our next clinical development steps for CT1812, which include a larger Phase 2 study. We look forward to a productive review and discussion at CTAD of these data and their implications for patients with Alzheimer’s disease.”
|Title:||Biomarker Outcomes from the Phase 1b/2a Safety Trial of the Anti-Aβ Oligomer Drug CT1812 in Alzheimer’s Patients (LBP28 – Late-Breaking Poster Session)|
|Time and Date:||November 2, 2017|
|Presenter:||Susan M. Catalano, Ph.D., of Cognition Therapeutics, Inc.|
|Title:||The Anti-Aβ Oligomer Drug CT1812 for Alzheimer’s: Phase 1b/2a Safety Trial Outcomes (LB13 – Oral Communications Session)|
|Time and Date:||November 4, 2017 at 10:30 a.m. ET|
|Presenter:||Lon S. Schneider, M.D., of the Keck School of Medicine of USC|
Cognition’s lead product candidate, CT1812, has completed a Phase 1b/2a clinical study (COG0102) in patients with mild-to-moderate Alzheimer’s disease and has been granted Fast Track designation by the US FDA. This highly brain penetrant compound targets the sigma-2 receptor complex on neuronal synapses, displacing toxic beta amyloid (Ab) oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss.
About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally available small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. CT1812 and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at http://www.cogrx.com.
This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.